Radiopharm Theranostics receives approval for study of PDL1-nanobody in lung cancer

Latest News

Australian company Radiopharm Theranostics (ASX:RAD) has been granted Human Research Ethics Committee approval to commence its first-in-human Phase 1 study in Australia for its therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC).

The company said the dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer.

The study will be conducted at Princess Alexandra Hospital in Brisbane, with the support of leading oncology care provider GenesisCare.

The company said the technology underpinning the trial is its proprietary nanobody from its NanoMab platform, which targets the PDL1 expression in NSCLC, the most common type of lung cancer. This is an area of high unmet need, and it added there is potential for the treatment to be the first-in-class radiopharmaceutical therapy targeting PDL1.